行情

GRFS

GRFS

基立福
NASDAQ

实时行情|Nasdaq Last Sale

20.65
+1.13
+5.79%
盘后: 21.27 +0.62 +3.00% 19:29 03/27 EDT
开盘
19.68
昨收
19.52
最高
20.70
最低
19.21
成交量
58.79万
成交额
--
52周最高
25.73
52周最低
13.40
市值
228.40亿
市盈率(TTM)
20.25
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测GRFS价格均价为26.75,最高价位26.75,最低价为26.75。

EPS

GRFS 新闻

更多
  • The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger
  • Benzinga · 2天前
  • Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
  • PR Newswire · 3天前
  • Spain's Grifols to test plasma therapy for COVID-19 with U.S. FDA
  • Reuters · 3天前
  • Coronavirus Toll Surges in Spain
  • Barrons.com · 03/21 17:52

所属板块

制药
-0.41%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

GRFS 简况

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries, such as Kiro Grifols SL.
展开

微牛提供Grifols SA - ADR(NASDAQ-GRFS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的GRFS股票新闻,以帮助您做出投资决策。